GenPharm International Case Solution
GenPharm was founded in 1989 and immediately became a leader in the area of transgenic animal technology. Between 1994 and 1991, the firm pursued cutting edge research in the area of transgenic animal technology, created cooperation agreements with several leading corporations, and raised millions of dollars. GenPharm's board determined not to carry on with the planned IPO, and change the nature of its business in 1995 and 1996 and the firm was compelled to reduce the size. In March 1997, the legal situation was concluded with a resolution and cross license arrangement. Soon afterwards, the board received an offer from a publicly traded biotechnology company, Medarex, Inc., to get GenPharm for up to $65 million. The case finishes requesting pupils to develop a recommendation for the GenPharm board with respect to the acquisition.
This is just an excerpt. This case is about STRATEGY & EXECUTION
PUBLICATION DATE: September 05, 2002